Publication of Circular

RNS Number : 7826S
Circassia Pharmaceuticals Plc
27 June 2018
 

27 JUNE 2018

CIRCASSIA PHARMACEUTICALS PLC

PUBLICATION OF CIRCULAR

 

On 24 April 2018, Circassia Pharmaceuticals plc (the Company) announced that, conditional on the approval of the Company's shareholders, it had agreed to amend certain terms of its development and commercialisation agreement (DCA) with AstraZeneca dated 17 March 2017 and to issue further shares to AstraZeneca in connection therewith (the Transaction).

 

The Company today announces the publication of a circular (the Circular) containing a notice of general meeting of the Company's shareholders to be convened at 12.00 on 16 July 2018 at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom (the General Meeting). At the General Meeting, the Company's independent shareholders will be asked to approve a special resolution to authorise the Transaction as a "related party transaction" under the Listing Rules. The procedures and timings for shareholders to vote on the special resolution are set out in the notice of the General Meeting in the Circular.

 

The Circular also includes an update on the Company's free float status and related undertakings to the FCA under the Listing Rules, including the potential move of the Company's listing to AIM. Further background and details regarding this matter are set out on pages 8 and 9 of the Circular.

 

The Circular and a Form of Proxy in relation to the General Meeting are being posted today, and the Circular will shortly be available for viewing, subject to regulatory requirements, on the Company's website at www.circassia.com/investors/. A copy of the Circular will also be submitted to the National Storage Mechanism and will shortly be available at www.morningstar.co.uk/uk/NSM.

For further information, please contact:

Circassia


Steve Harris, Chief Executive Officer

Tel: +44 (0) 1865 405 560

Julien Cotta, Chief Financial Officer


Rob Budge, Corporate Communications




JP Morgan Cazenove


James Mitford / James Deal

Tel: +44 (0) 20 7742 4000



Numis Securities


Clare Terlouw / Freddie Barnfield

Tel: +44 (0) 20 7260 1000



FTI Consulting


Simon Conway / Mo Noonan

Tel: +44 (0) 20 3727 1000

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CIRLLFFLRIIDFIT

Companies

Niox Group (NIOX)
UK 100

Latest directors dealings